Advocacy Actions
Comments to the Guangdong Pharmaceutical Trading Centre on Coronary Balloon Catheter Group Procurement
The Healthcare Equipment Working Group submitted comments to the draft procedure of the Guangdong Pharmaceutical Trading Centre on coronary balloon catheter group procurement.
Read more5th China Medical Device Vigilance Conference
The 5th China Medical Device Vigilance Conference was held on 2 December.
Read moreCall for Comments on MEE National Carbon Emissions Trading Management Measures (Trial) (Draft for Comments) 中国欧盟商会对生态环境部《全国碳排放权交易管理办法（试行）》（征求意见稿）的反馈意见
Carbon market working group submitted the comments to MEE on National Carbon Emissions Trading Management Measures (Trial) (Draft for Comments). The members of environment and energy working groups attache the attention to this rule as well.
Read moreComments on the Interim Provisions on the Administration of Domestic Agents of Overseas Marketing Authorization Holders (Trial) to the National Medical Products Administration
European Chamber Pharmaceutical working group submitted comments on the Interim Provisions on the Administration of Domestic Agents of Overseas Marketing Authorization Holders (Trial) to the NMPA
Read moreConference-call with CBIRC on Cross-selling Insurance Products
Many foreign insurance companies do not hold a cross selling qualification in China, whereas in the past, foreign insurance companies that have obtained this qualification only aim at selected business lines. As old-style applications for cross-selling licenses were stopped while back members have been in a kind of vacuum on this matter. In this conference-call, the progress on re-open applications for cross-selling of insurance products for insurance companies was discussed. It was also discussed what consumer finance companies and auto finance companies that wish to act as an intermediate of insurance and expect to see in terms of regulatory developments.
Read moreComments to the SAMR on Guidelines for Anti-monopoly in the Field of Platform Economy (Draft for Comment)
The Legal and Compliance WGs submitted comments to the SAMR on Guidelines for Anti-monopoly in the Field of Platform Economy (Draft for Comment).
Read moreComments on Measures for the Supervision and Administration of Online Drug Sales to the National Medical Products Administration
European Chamber Pharmaceutical working group submitted comments on Measures for the Supervision and Administration of Online Drug Sales to the NMPA
Read moreLetter to the Department of General Operation, General Administration of Customs China (GACC) Posing Questions on the New Commercial Cryptography Import Licence and Export Control Lists
The European Chamber sent a letter to the Department of General Operation, General Administration of Customs China (GACC) posing questions on the new to-be-released Commercial Cryptography Import Licence and Export Control Lists.
Read moreComments to the National Medical Products Administration (NMPA) on Document Requirements for Cosmetic Product Registrations and Notifications, Document Requirements for New Ingredient Registrations and Notifications, and Document Requirements for Guidelin
On 30th November 2020, the Cosmetics Working Group submitted comments to NMPA upon Document Requirements for Cosmetic Product Registrations and Notifications, Document Requirements for New Ingredient Registrations and Notifications, and Document Requirements for Guidelines for the Evaluation of Cosmetic Efficacy Claims regarding articles with different opinions from member companies.
Read moreEuropean Chamber representatives meet with Commission Deputy Director-General Khalil Rouhana
On Monday, 30th November, a number of industry representatives of the European Chamber led by President Joerg Wuttke met with the Deputy Director-General for DG CONNECT Mr Khalil Rouhana.
Read more